NL8400641A - Analgetische preparaten. - Google Patents
Analgetische preparaten. Download PDFInfo
- Publication number
- NL8400641A NL8400641A NL8400641A NL8400641A NL8400641A NL 8400641 A NL8400641 A NL 8400641A NL 8400641 A NL8400641 A NL 8400641A NL 8400641 A NL8400641 A NL 8400641A NL 8400641 A NL8400641 A NL 8400641A
- Authority
- NL
- Netherlands
- Prior art keywords
- tizanidine
- paracetamol
- preparation according
- preparation
- pain
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 21
- 230000000202 analgesic effect Effects 0.000 title claims description 14
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 40
- 229960005489 paracetamol Drugs 0.000 claims description 40
- 229960000488 tizanidine Drugs 0.000 claims description 35
- XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 12
- 229960004704 dihydroergotamine Drugs 0.000 claims description 7
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000000829 suppository Substances 0.000 claims description 5
- 206010043269 Tension headache Diseases 0.000 claims description 3
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 3
- 208000001407 Vascular Headaches Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000000748 compression moulding Methods 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 208000002193 Pain Diseases 0.000 description 19
- 230000036407 pain Effects 0.000 description 18
- 239000003826 tablet Substances 0.000 description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 11
- ZWUKMNZJRDGCTQ-UHFFFAOYSA-N Tizanidine hydrochloride Chemical compound Cl.ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 ZWUKMNZJRDGCTQ-UHFFFAOYSA-N 0.000 description 6
- 229960002388 tizanidine hydrochloride Drugs 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 208000007101 Muscle Cramp Diseases 0.000 description 4
- 229920003110 Primojel Polymers 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 231100000304 hepatotoxicity Toxicity 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 229960000807 dihydroergotamine mesylate Drugs 0.000 description 2
- ADYPXRFPBQGGAH-UMYZUSPBSA-N dihydroergotamine mesylate Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-UMYZUSPBSA-N 0.000 description 2
- 230000007056 liver toxicity Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- -1 2-imidazolin-2-yl-amino Chemical group 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 206010065016 Post-traumatic pain Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000003108 foot joint Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB838306473A GB8306473D0 (en) | 1983-03-09 | 1983-03-09 | Analgesic preparations |
| GB8306473 | 1983-03-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8400641A true NL8400641A (nl) | 1984-10-01 |
Family
ID=10539240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8400641A NL8400641A (nl) | 1983-03-09 | 1984-02-29 | Analgetische preparaten. |
Country Status (23)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5037658A (en) * | 1989-09-14 | 1991-08-06 | Hoechst-Roussel Pharmaceuticals, Inc. | Direct dry compressible acetaminophen composition |
| US5130140A (en) * | 1989-09-14 | 1992-07-14 | Hoeschst-Roussel Pharmaceuticals Inc. | Method of making direct dry compressible acetaminophen composition |
| US5198228A (en) * | 1989-09-14 | 1993-03-30 | Hoechst-Roussel Pharmaceuticals Inc. | Direct dry compressible acetaminophen tablet |
| DE4327462A1 (de) * | 1993-08-16 | 1995-02-23 | Carl Heinrich Dr Weischer | Neue N-Acetyl-p-Aminophenol-Derivate zur Bekämpfung von Schmerzzuständen |
| US8329734B2 (en) * | 2009-07-27 | 2012-12-11 | Afgin Pharma Llc | Topical therapy for migraine |
| US20050100594A1 (en) * | 2003-11-12 | 2005-05-12 | Nilendu Sen | Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor |
| WO2005046648A1 (en) * | 2003-11-12 | 2005-05-26 | Glenmark Pharmaceuticals Ltd. | Extended release pharmaceutical dosage forms comprising alpha-2 agonist tizanidine |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3012837A1 (de) * | 1979-04-10 | 1980-10-30 | Sandoz Ag | Analgetische und myotonolytische praeparate |
-
1983
- 1983-03-09 GB GB838306473A patent/GB8306473D0/en active Pending
-
1984
- 1984-02-29 NL NL8400641A patent/NL8400641A/nl not_active Application Discontinuation
- 1984-02-29 DK DK148884A patent/DK148884A/da not_active Application Discontinuation
- 1984-02-29 HU HU84817A patent/HUT34885A/hu not_active IP Right Cessation
- 1984-03-01 CH CH1010/84A patent/CH660303A5/de not_active IP Right Cessation
- 1984-03-01 DE DE19843407579 patent/DE3407579A1/de not_active Withdrawn
- 1984-03-01 FR FR8403349A patent/FR2542195B1/fr not_active Expired
- 1984-03-02 BE BE1/10973A patent/BE899058A/fr not_active IP Right Cessation
- 1984-03-06 IT IT8447808A patent/IT8447808A0/it unknown
- 1984-03-07 SE SE8401263A patent/SE8401263L/xx not_active Application Discontinuation
- 1984-03-07 ES ES530359A patent/ES8608867A1/es not_active Expired
- 1984-03-07 IL IL71176A patent/IL71176A/xx not_active IP Right Cessation
- 1984-03-07 DD DD84260658A patent/DD216383A5/de unknown
- 1984-03-07 CA CA000449005A patent/CA1228817A/en not_active Expired
- 1984-03-07 GR GR74017A patent/GR82005B/el unknown
- 1984-03-07 NZ NZ207411A patent/NZ207411A/en unknown
- 1984-03-07 PT PT78208A patent/PT78208B/pt unknown
- 1984-03-07 AU AU25355/84A patent/AU2535584A/en not_active Abandoned
- 1984-03-08 US US06/587,571 patent/US4515802A/en not_active Expired - Fee Related
- 1984-03-08 JP JP59045358A patent/JPS59170014A/ja active Pending
- 1984-03-08 LU LU85242A patent/LU85242A1/fr unknown
- 1984-03-09 ZA ZA841783A patent/ZA841783B/xx unknown
- 1984-03-09 PH PH30376A patent/PH20258A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE3407579A1 (de) | 1984-09-13 |
| PT78208B (en) | 1986-07-15 |
| DD216383A5 (de) | 1984-12-12 |
| ES530359A0 (es) | 1986-09-01 |
| DK148884D0 (da) | 1984-02-29 |
| ZA841783B (en) | 1985-10-30 |
| ES8608867A1 (es) | 1986-09-01 |
| PT78208A (en) | 1984-04-01 |
| LU85242A1 (fr) | 1984-11-14 |
| AU2535584A (en) | 1984-09-13 |
| DK148884A (da) | 1984-09-10 |
| GR82005B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1984-12-12 |
| US4515802A (en) | 1985-05-07 |
| CH660303A5 (de) | 1987-04-15 |
| PH20258A (en) | 1986-11-14 |
| NZ207411A (en) | 1987-07-31 |
| JPS59170014A (ja) | 1984-09-26 |
| SE8401263D0 (sv) | 1984-03-07 |
| IL71176A (en) | 1988-02-29 |
| SE8401263L (sv) | 1984-09-10 |
| FR2542195A1 (fr) | 1984-09-14 |
| GB8306473D0 (en) | 1983-04-13 |
| BE899058A (fr) | 1984-09-03 |
| HUT34885A (en) | 1985-05-28 |
| CA1228817A (en) | 1987-11-03 |
| FR2542195B1 (fr) | 1987-01-23 |
| IT8447808A0 (it) | 1984-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI82187B (fi) | Foerfarande foer framstaellning av lagerstabila snabbsoenderfallande farmaceutiska aktivaemnespresstycken. | |
| KR102803917B1 (ko) | 루카파립의 고 용량 강도 정제 | |
| KR100728846B1 (ko) | 약물 함유량이 높은 정제 | |
| KR100634253B1 (ko) | 초강력 붕해제를 사용한 고속-용해 에파비렌즈 캡슐 또는정제 및 그의 제조 방법 | |
| KR100202154B1 (ko) | 파라세타몰 및 돔페리돈을 함유한 필름 피복 정제 | |
| IE883679L (en) | Controlled release combination of carbidopa/levodopa | |
| PL200957B1 (pl) | Kompozycja farmaceutyczna celecoxib'u i zastosowanie kompozycji farmaceutycznej | |
| AU2009349125B2 (en) | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application | |
| KR20000075897A (ko) | 파라세타몰을 포함하는 경구용 정제 | |
| SK3302004A3 (sk) | Tuhé liekové formy s riadeným uvoľňovaním účinnej látky - nový systém dodávania liečiva so zníženým rizikom nekontrolovaného uvoľňovania účinnej látky | |
| JPS61183220A (ja) | 鎮痛性を有する医薬組成物 | |
| JPS6379833A (ja) | 月経困難症及び／又は月経前症候群の軽減用薬剤組成物とその調製法 | |
| CS247190B2 (en) | Method of agent with porous matrix production on polycaprolactam base | |
| JPH10512573A (ja) | セスキテルペンラクトンとビタミンｂ複合体とを含む片頭痛およびその他の疾病治療用複合剤 | |
| NL8400641A (nl) | Analgetische preparaten. | |
| WO2006123213A1 (en) | Modified release formulations of gliclazide | |
| JP3982889B2 (ja) | イブプロフェン含有医薬製剤 | |
| GB2135884A (en) | Analgesic preparations containing tizanidine and paracetamol | |
| JPS63132834A (ja) | 鎮静剤製剤 | |
| KR101254511B1 (ko) | 위장약 조성물 | |
| HU186719B (en) | Process for producing pharmaceutical compositions containing meptazinol and ibuprophene or pharmaceutically acceptable salts thereof | |
| US20030004130A1 (en) | Homogeneous pharmaceutical compositions containing zidovudine and lamivudine | |
| HK1001822B (en) | Medicinal form for oral application for the once-a-day treatment of hypertension by diltiazem hydrochloride | |
| HK1001822A1 (en) | Medicinal form for oral application for the once-a-day treatment of hypertension by diltiazem hydrochloride | |
| EP1267861B1 (en) | Composition comprising paracetamol and niflumic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A85 | Still pending on 85-01-01 | ||
| BV | The patent application has lapsed |